StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 7.5
Power Rank trend -> Rising
03/27/2025 16:14:00 EST
Exelixis Inc (EXEL)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, EXEL has been trading in a range between $39.16 and $36.36 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
EXEL is trading below resistance at $39.16, about 6% to the upside. There is support at $35.61 -3% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Exelixis Inc $EXEL entered a Green zone 28 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $34.4709, a potential down side of -6.86% from the recent price of 37.01. The stock is trading 8.13% (potential upside) below its 52 week high of $40.02 and 83.76 % (potential downside) above its 52 week low of $20.14 - based on the recent price.
Company Summary
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
News
| FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors. Source: Zacks Investment Research Thu, 27 Mar 2025 16:00:24 -0400 Sentiment: Positive |
| Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders. Source: Zacks Investment Research Wed, 26 Mar 2025 16:01:07 -0400 Sentiment: Positive |
| Here's Why Exelixis (EXEL) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. Source: Zacks Investment Research Wed, 26 Mar 2025 10:45:32 -0400 Sentiment: Positive |
| Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET); and 2) adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or. Source: Business Wire Wed, 26 Mar 2025 09:15:00 -0400 Sentiment: Neutral |
| Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL. “We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our commitment to the discovery and development of innovative cancer treatments,” said Dana T. Aftab, Ph.D., Executive Vice. Source: Business Wire Tue, 25 Mar 2025 17:15:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 40.02 52 Week Low: 20.14 Beta: 0.574 50 Day MA: 35.7266 200 Day MA: 30.1269 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0.754 Qtr Revenue Growth YOY: 0.182 Forward PE: 17.9533 Trailing PE: 21.0514